We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 45.50
Bid: 45.00
Ask: 46.00
Change: 1.00 (2.25%)
Spread: 1.00 (2.222%)
Open: 44.75
High: 45.75
Low: 45.50
Prev. Close: 44.50
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: Stocks slip as investors brace for Fed testimony

Mon, 10th Jan 2022 12:16

(Alliance News) - Stock prices in London were lower at midday on Monday as investors prepare for the prospect of more aggressive monetary policy from the US Federal Reserve.

The FTSE 100 index was down 12.45 points, or 0.2%, at 7,472.87. The mid-cap FTSE 250 index was down 60.97 points, or 0.3%, at 23,292.28. The AIM All-Share index was down 4.15 points, or 0.4%, at 1,183.19.

The Cboe UK 100 index was down 0.1% at 741.04. The Cboe 250 was down 0.2% at 20,778.02, but the Cboe Small Companies was up 0.1% at 15,593.25.

In Paris, the CAC 40 stock index was down 0.2%, while the DAX 40 in Frankfurt was 0.3% lower.

New York was pointed to a flat-to-lower open following a lower close on Friday with equity markets seeing an up-and-down start to 2022.

Dow Jones Industrial Average was called marginally higher, the S&P 500 down 0.5%, and the Nasdaq Composite down 1.3% based on futures trading.

Key data points this week will be consumer price index readings from the US and China on Wednesday, as the global economy contends with higher energy costs, supply chain blockages, and the fast-spreading Omicron variant of Covid-19.

The Fed faces a tough balancing act of having to adjust monetary policy to rein in prices while at the same time avoid hindering the economic recovery.

The US central bank has already started tapering its vast bond-buying programme, put in place at the start of the pandemic, and has signalled it could start lifting interest rates from record lows from March, with some observers predicting multiple hikes this year.

Fed Chair Jerome Powell will testify before the Senate Banking Committee on Tuesday.

Analysts at ActivTrades said: "Market volatility continues to grow almost everywhere for the beginning of the new year as lingering uncertainties keep pressure on market sentiment. Investors are still digesting the sooner-than-expected hawkish pivot from the Fed, with the first rate hike now anticipated in the first quarter (March) as well as further rises expected later in the year. The huge hit and impact of the Omicron strain on economies combined with the prospect of withdrawn liquidity from central banks is denting investors' appetite for riskier assets in the short-term.

"Traders are likely to wait for new major market drivers before pushing stock prices in new directions. All eyes will remain on monetary policy this week with a new batch of comments from major Fed speakers alongside the crucial US inflation report on Wednesday."

In the FTSE 100, housebuilders were the worst performers after the UK government announced plans to resolve the flammable cladding crisis.

Persimmon was down 4.7%, Barratt Developments down 3.6%, Taylor Wimpey down 2.5%, and Berkeley Group down 2.5%. Midcap builders Redrow, Bellway and Countryside were off 3.9%, 3.3% and 3.1% respectively.

Developers in the UK must agree a GBP4 billion plan to fix dangerous cladding on low-rise flats by early March or risk new laws forcing them to act, Housing Secretary Michael Gove has said.

The Cabinet minister threatened that he is "prepared to take all steps necessary" to fix the "broken system" in a letter to the industry ahead of detailing the plans on Monday. Potential action also includes restricting access to government funding and future procurements, the use of planning powers, and pursuing firms through the courts.

The proposals to alleviate the scandal that has trapped leaseholders in unsafe and unsellable homes come more than four years after the Grenfell Tower fire in June 2017, in which 72 people were killed. Leaseholders in buildings between 11 metres and 18m tall will no longer have to take out loans to cover the costs of remediation work despite no new money coming from the Treasury.

Instead, Gove told developers to agree to start contributing this year to cover the "full outstanding cost", which he estimates to be GBP4 billion.

"Many flat owners have been left with onerous costs for replacing flammable cladding and the latest reports on who will foot the bill should come as no surprise to the sector in that context," said AJ Bell's Russ Mould. "The housebuilders have benefited from generous incentives, such as Help to Buy and the mortgage guarantee scheme, in recent years. However, state support is not a one-way street, and the sector needs to do its bit to look after its customers."

Experian was down 2.4% after Morgan Stanley downgraded the credit checking agency to Equal Weight from Overweight.

In the FTSE 250, Plus500 was up 2.8%. The contract-for-difference trading provider hailed an "outstanding" operational and financial performance throughout 2021 that exceeded market expectations.

For 2021, Plus500 said revenue is estimated around USD718 million, supported by customer income - a key underlying growth metric - of USD702 million. The revenue figure is below the USD872.5 million posted in 2020, but higher than the company-compiled consensus analyst forecast of USD655.2 million.

In addition, Plus500 said that it was considering a new share buyback programme, following the completion of the USD12.6 million buyback scheme announced in October.

On AIM, Avacta was down 27% after the cancer-focused immunotherapies developer halted the sales of its AffiDX antigen test due to its lower sensitivity to detecting the Omicron variant of Covid-19.

Avacta said that the cause for the lower sensitivity of the test is the antibody with which the company Affimer is paired. As a result, Avacta has paused sales of the antigen test as it works to replace the antibody in the product to improve its performance.

The pound was quoted at USD1.3587 at midday on Monday, up from USD1.3572 at the London equities close Friday.

The euro stood at USD1.1327, lower against USD1.1343. Against the Japanese yen, the dollar was trading at JPY115.77, up from JPY115.64.

On the economic front, the unemployment rate in the eurozone continued to edge down in November. Figures released from Eurostat showed the euro area unemployment rate stood at 7.2% in November, down from 7.3% in October.

The reading, in line with market forecasts, also was down from 7.4% in November 2020 and the 7.3% reported for February 2020, the month before the pandemic began to hit Europe.

"The outlook for unemployment remains quite bright," Dutch bank ING said of the eurozone report. "Continued declines over the coming months are likely, although the re-entry of people to the labour market could slow the pace over the course of 2022. Nevertheless, this job market strength is set to feed through to wage negotiations and adds to medium-term expectations of inflation of around 2%. The ECB will take note as it considers the next steps in policy normalisation after its recent announcement of reducing asset purchases."

Brent oil was quoted at USD81.61 a barrel Monday at midday, down from USD81.99 late Friday. Gold stood at USD1,793.19 an ounce, marginally higher from USD1,791.80.

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
23 Apr 2024 14:26

UK earnings, trading statements calendar - next 7 days

Wednesday 24 April 
1Spatial PLCFull Year Results
abrdn PLCTrading Statement
Ecora Resources PLCTrading Statement
Fresnillo PLCTrading Statement
Lloyds Banking Group PLCQ1 Results
Nichols PLCTrading Statement
PensionBee Group PLCFirst Quarter Results
PZ Cussons PLCTrading Statement
Quilter PLCQ1 Results
Reckitt Benckiser Group PLCTrading Statement
Sanderson Design Group PLCFull Year Results
Serica Energy PLCFull Year Results
Star Energy Group PLCFull Year Results
Tortilla Mexican Grill PLCFull Year Results
Tracsis PLCHalf Year Results
Warpaint London PLCFull Year Results
Thursday 25 April 
Aquila European Renewables PLCFull Year Results
Argo Blockchain PLCFull Year Results
AstraZeneca PLCQ1 Results
Barclays PLCQ1 Results
Checkit PLCFull Year Results
Coca-Cola Europacific Partners PLCTrading Statement
Destiny Pharma PLCFull Year Results
Dillistone Group PLCFull Year Results
Focusrite PLCHalf Year Results
Gem Diamonds LtdTrading Statement
Hikma Pharmaceuticals PLCTrading Statement
Hummingbird Resources PLCTrading Statement
Ibstock PLCTrading Statement
Inchcape PLCTrading Statement
J Sainsbury PLCFull Year Results
London Stock Exchange Group PLCQ1 Results
Persimmon PLCTrading Statement
Pinewood Technologies Group PLCFull Year Results
PPHE Hotel Group LtdTrading Statement
PureTech Health PLCFull Year Results
Relx PLCTrading Statement
Renewi PLCTrading Statement
Schroders PLCQ1 Results
Skillcast Group PLCFull Year Results
Travis Perkins PLCTrading Statement
Trifast PLCTrading Statement
Unilever PLCQ1 Results
WAG Payment Solutions PLCTrading Statement
Weir Group PLCTrading Statement
WH Smith PLCHalf Year Results
WPP PLCTrading Statement
Zinc Media Group PLCFull Year Results
Friday 26 April 
Facilities by ADF PLCFull Year Results
Kingspan Group PLCTrading Statement
NatWest Group PLC Q1 Results
Pearson PLCTrading Statement
Record PLCTrading Statement
Smurfit Kappa Group PLCTrading Statement
Taylor Maritime Investments LtdTrading Statement
Monday 29 April 
Beazley PLCTrading Statement
Biome Technologies PLCFull Year Results
Christie Group PLCFull Year Results
Gresham Technologies PLCFull Year Results
Jadestone Energy PLCFull Year Results
Oxford BioMedica PLCFull Year Results
SpaceandPeople PLCFull Year Results
Tuesday 30 April 
Avacta Group PLCFull Year Results
Card Factory PLCFull Year Results
Capital & Regional PLCFull Year Results
Coca-Cola HBC AGTrading Statement
Elementis PLCTrading Statement
essensys PLCHalf Year Results
Fadel Partners IncFull Year Results
Glencore PLCTrading Statement
Hargreaves Lansdown PLC Trading Statement
Howden Joinery PLCTrading Statement
HSBC Holdings PLCQ1 Results
Kelso Group PLCFull Year Results
Northcoders Group PLCFull Year Results
Phoenix Spree Deutschland LtdFull Year Results
RBG Holdings PLCFull Year Results
Rotork PLCTrading Statement
Safestore Holdings PLCHalf Year Results
Shield Therapeutics PLCFull Year Results
St James's Place PLCTrading Statement
Whitbread PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
22 Apr 2024 17:51

TRADING UPDATES: First Tin updates Tellerhauser estimates

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
21 Mar 2024 13:10

Avacta reaches milestone in AVA6000 dose escalation

(Sharecast News) - Avacta Group announced a significant milestone in its phase 1a dose escalation study of AVA6000, its lead 'preCISION' drug, on Thursday.

Read more
21 Mar 2024 10:37

Avacta doses third patient in drug conjugate trial for tumour tissue

(Alliance News) - Avacta Group PLC on Thursday said it dosed the third patient in the first cohort of its phase 1a dose escalation study for its lead preCision drug AVA6000.

Read more
18 Mar 2024 14:31

IN BRIEF: Avacta shareholders give AGM go-ahead to issue new shares

Avacta Group PLC - Wetherby, England-based life sciences company developing oncology drugs and diagnostics - At annual general meeting on Monday, shareholders approved the resolution to issue 23.9 million placing shares and 10.9 million Rex offer share, both at 50 pence each. This raises gross proceeds of around GBP11.9 million and GBP5.4 million respectively. Combined with proceeds from an earlier firm placing and direct subscription, the shares for which were admitted to trading on March 4, Avacta has raised total gross proceeds of GBP31.1 million.

Read more
5 Mar 2024 17:09

EARNINGS AND TRADING: Harland & Wolff wins major Falklands contract

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
29 Feb 2024 12:18

Avacta increases placing size to GBP26 million thanks to strong demand

(Alliance News) - Avacta Group PLC on Thursday said it is increasing its placing to GBP25.7 million, "in light of the strong demand."

Read more
29 Feb 2024 10:27

AIM WINNERS & LOSERS: Beacon Energy and Avacta fall on fundraise

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Read more
29 Feb 2024 08:27

Avacta tumbles after raising £25.7m in heavily discounted placing

(Sharecast News) - Healthcare therapeutics company Avacta tumbled on Thursday after a heavily discounted placing.

Read more
28 Feb 2024 20:31

TRADING UPDATES: Avacta plans fundraise to fund clinical development

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
19 Jan 2024 11:18

Avacta appoints new head of research and development

(Sharecast News) - Oncology drugs and diagnostics developer Avacta announced the appointment of Dr Christina Coughlin as its new head of research and development for the therapeutics division on Friday.

Read more
19 Jan 2024 09:11

IN BRIEF: Avacta says new head of R&D Coughlin brings "deep expertise"

Avacta Group PLC - Wetherby, England-based life sciences company developing oncology drugs and diagnostics - Appoints Christina Coughlin as head of research and development. Coughlin, who will take up the position on February 1, has served as a non-executive director of Avacta since March 2022 and was appointed consultant in interim in September 2023. She previously served as chief executive officer of Cytoimmune Therapeutics LLC, a clinical stage biotechnology company focused on novel cancer immunotherapy products. In the new role, Coughlin will oversee clinical and pre-clinical research and development activities for the company's therapeutics division, while retaining her position on as an executive director of Avacta. The company says that Coughlin has been "pivotal" in the development strategy for its AVA6000 tumour-targeted therapy.

Read more
19 Dec 2023 10:24

Avacta appoints new chief business officer

(Sharecast News) - Oncology drugs and diagnostics specialist Avacta Group announced the appointment of Dr Simon Bennett as the chief business officer of its therapeutics division on Tuesday.

Read more
19 Dec 2023 09:57

IN BRIEF: Avacta taps biopharma veteran as Therapeutics business chief

Avacta Group PLC - Wetherby, England-based life sciences company developing oncology drugs and diagnostics - Hires Simon Bennett as chief business officer of Therapeutics division. Says Bennett has over 26 years of commercial experience in the biopharma industry and has "worked with" various large and mid-sized companies like Bristol-Myers Squibb Co and Menarini Group.

Read more
13 Dec 2023 11:49

Avacta says study shows cancer treatment AVA6000 working as planned

(Alliance News) - Avacta Group PLC on Wednesday celebrated strong results from its latest cancer-targeting study, which showed the release of a chemotherapy to the tumour as intended.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.